Globus Medical Inc. Class A Common Stock vs Williams-Sonoma, Inc. — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Williams-Sonoma, Inc. trades at $243.14 (market cap $28.26B). The key difference: Williams-Sonoma, Inc. is far larger — about 2.8× Globus Medical Inc. Class A Common Stock's market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Williams-Sonoma, Inc. for 59 Days on average.
| GMED | WSM | |
|---|---|---|
Market Cap | $10.25B | $28.26B |
Volume | 1,108,124 | 1,108,410 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $251.81 |
52-Week Low | $58.33 | $168.64 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $9.76B | $28.76B |
Dividend Yield | — | 1.27% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Williams-Sonoma (WSM) trades at $242.48, up 1.52% recently, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Profitability remains robust, with a net income margin of 14.73% and ROE of 54.96%, while valuation ratios like P/E of 24.61 and P/S of 3.62 reflect market confidence. Recent news highlights growth through minimal discounting and AI integration, supporting positive sentiment.
The outlook for WSM is favorable, driven by earnings momentum and market share gains, but risks include housing market sensitivity and competitive pressures. Analyst consensus leans hold with a $246.31 price target, suggesting modest upside. Institutional interest is steady, though insider selling warrants monitoring. Overall, the stock presents a balanced opportunity with growth potential tempered by sector-specific headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →